BPC-157 Therapy The BPC-157 peptide is characterized by its ability to inhibit the increased expression of -defensins, LL-37, RNase 7, psoriasin, and lysozyme, which may make it one of the main factors responsible for reduced susceptibility to skin infections in patients with psoriasis
With no head-to-head data, comparing the two requires stitching together studies that differ in species, model, route, endpoint, and molecule a chain with several weak links
published a 2025 systematic review on BPC-157 in orthopedic sports medicine (HSS Journal)
Swisschems built its reputation slightly differently
GIP has been shown to decrease food intake while blunting the metabolic adaptive responses that usually occur with calorie restriction resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids